Members
VB04 - Let's interpret some variants (1)
In this briefing, we walk you through a step-by-step process of the resources you can access to assess variant pathogenicity and actionability.
Samantha Hasenleithner
from Graz / 4 postsSamantha has been working with ctDNA applications for monitoring of treatment response, identifying markers of resistance, and matching drugs to actionable targets.
Members
Understanding and estimating tumor fraction from plasma cell-free DNA
Vessel Tutorial - Understanding liquid biopsy results is highly dependent on tumor fraction of the cell-free DNA sample. Without information about ctDNA content from plasma, variant allele frequencies and uninformative testing results are very difficult to interpret.
Members
Members
ctDNA profiling case studies
In this condensed tutorial, Vessel presents three real-world cases of patients with confirmed progressive disease in which liquid biopsy was used to identify actionable targets. The tutorial also includes a brief summary of the patient's history and the results of the liquid biopsy.